AstraZeneca PLC (NASDAQ:AZN – Get Rating) – Equities research analysts at SVB Leerink increased their Q1 2022 earnings per share (EPS) estimates for shares of AstraZeneca in a report issued on Thursday, April 28th. SVB Leerink analyst A. Berens now anticipates that the company will earn $0.82 per share for the quarter, up from their previous forecast of $0.78. SVB Leerink currently has a “Outperform” rating and a $70.00 price target on the stock. SVB Leerink also issued estimates for AstraZeneca’s FY2022 earnings at $3.32 EPS.
Other equities research analysts also recently issued research reports about the company. Credit Suisse Group lifted their target price on AstraZeneca from GBX 9,000 ($114.71) to £110 ($140.20) in a research report on Friday, April 8th. JPMorgan Chase & Co. lifted their price objective on AstraZeneca from £100 ($127.45) to £120 ($152.94) in a research note on Thursday, April 7th. DZ Bank raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Friday, February 11th. Deutsche Bank Aktiengesellschaft lifted their price objective on AstraZeneca from £105 ($133.83) to £115 ($146.57) in a research note on Wednesday, April 6th. Finally, TheStreet raised AstraZeneca from a “c+” rating to a “b-” rating in a research note on Thursday, March 10th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $7,223.13.
AstraZeneca (NASDAQ:AZN – Get Rating) last posted its earnings results on Thursday, February 10th. The company reported $0.84 EPS for the quarter, beating the Zacks’ consensus estimate of $0.77 by $0.07. AstraZeneca had a return on equity of 27.48% and a net margin of 0.30%. The company had revenue of $11.50 billion for the quarter, compared to the consensus estimate of $11.06 billion. During the same quarter in the previous year, the business earned $0.54 earnings per share. The company’s revenue for the quarter was up 55.2% on a year-over-year basis.
The business also recently announced a semi-annual dividend, which was paid on Monday, March 28th. Investors of record on Friday, February 25th were paid a dividend of $0.985 per share. This represents a yield of 2.4%. This is a boost from AstraZeneca’s previous semi-annual dividend of $0.45. The ex-dividend date was Thursday, February 24th. AstraZeneca’s payout ratio is presently 1,378.67%.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AZN. Thomas White International Ltd. lifted its holdings in AstraZeneca by 5.9% during the 3rd quarter. Thomas White International Ltd. now owns 37,237 shares of the company’s stock worth $2,237,000 after buying an additional 2,063 shares during the last quarter. Wellington Management Group LLP lifted its holdings in AstraZeneca by 9.3% during the 3rd quarter. Wellington Management Group LLP now owns 53,145,564 shares of the company’s stock worth $3,191,923,000 after buying an additional 4,526,346 shares during the last quarter. Haverford Trust Co lifted its holdings in AstraZeneca by 10.6% during the 3rd quarter. Haverford Trust Co now owns 4,414 shares of the company’s stock worth $265,000 after buying an additional 424 shares during the last quarter. Banco Santander S.A. lifted its holdings in AstraZeneca by 172.3% during the 3rd quarter. Banco Santander S.A. now owns 21,730 shares of the company’s stock worth $1,305,000 after buying an additional 13,750 shares during the last quarter. Finally, Pura Vida Investments LLC purchased a new stake in AstraZeneca during the 3rd quarter worth about $3,003,000. 20.54% of the stock is owned by hedge funds and other institutional investors.
About AstraZeneca (Get Rating)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Get a free copy of the StockNews.com research report on AstraZeneca (AZN)
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
- Iridium Communications Stock is Ready to Return to Orbit
- There’s An Institutional Floor In Keurig Dr. Pepper
- Ford Falls Despite Optimistic Outlook
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.